• Lypressin Acetate: Experimental Workflows and Translational

  2026-05-21

  Lypressin acetate stands apart as a versatile vasopressin analog, powering advanced antidiuretic and vasoconstriction research with robust, reproducible signaling. This guide delivers stepwise protocols, troubleshooting insights, and practical tips for leveraging APExBIO’s Lypressin acetate across both classic and emerging translational domains.

• GANT61: Selective GLI Inhibitor for Cancer Research Applicat

  2026-05-20

  GANT61 is a selective GLI inhibitor used to suppress GLI-mediated transcription in cancer research. It demonstrates potent anti-proliferative and tumor growth suppression effects by targeting GLI1/2, critical effectors of the Hedgehog pathway. APExBIO provides validated protocols and product support for robust research outcomes.

• AZD2461: Novel PARP Inhibitor for Breast Cancer Research

  2026-05-20

  AZD2461 offers precision in targeting DNA repair pathways and overcomes Pgp-mediated resistance, making it a standout in breast cancer research. Its robust cytotoxicity and unique pharmacological profile enable more reliable in vitro and in vivo modeling for BRCA1-mutated tumors.

• Macrolide Antibiotics as Senolytics: Mechanistic Insights an

  2026-05-19

  Ozsvari et al. (2018) identified Azithromycin and Roxithromycin as selective senolytic agents that efficiently eliminate senescent human fibroblasts, without affecting non-senescent cells. Their work reveals new mechanistic connections between macrolide antibiotics, cellular metabolism, and senescence, opening translational avenues for drug repurposing and aging research.

• KR-12 Peptide–Cu(II) Interactions: Quantum Insights and Anti

  2026-05-19

  This article examines the 2024 Dalton Transactions study that combines quantum chemical modeling with experimental titration to elucidate how the smallest human antimicrobial peptide, KR-12, interacts with copper(II) ions. The findings reveal the primary binding sites and coordination modes, advancing our understanding of KR-12’s structure–activity relationships and informing future peptide engineering for antimicrobial and immunomodulatory applications.

• TRIM21 Drives ERK1/2-Mediated Drug Resistance in Pituitary T

  2026-05-18

  This study reveals TRIM21 as a critical oncogenic driver of cell proliferation and drug resistance in pituitary adenomas via ERK1/2 ubiquitination and phosphorylation. The work identifies Quisinostat as a candidate small-molecule inhibitor that downregulates TRIM21, suggesting a novel therapeutic approach for dopamine agonist-resistant pituitary tumors.

• Targeting FGFR2 Fusions in ICC via Cho-HDO and Asparagine De

  2026-05-18

  This study introduces a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide (Cho-HDO) that specifically suppresses FGFR2 fusion oncogenes in intrahepatic cholangiocarcinoma (ICC). By combining Cho-HDO treatment with asparagine depletion strategies, the research demonstrates a synergistic approach to overcoming resistance and improving therapeutic specificity against FGFR2 fusion-driven ICC.

• Ciclesonide (SKU B3477): Reliable Solutions for Cell Assays

  2026-05-17

  This article addresses laboratory challenges in cell viability, proliferation, and cytotoxicity assays, highlighting how Ciclesonide (SKU B3477) from APExBIO offers reproducible, data-driven solutions. Scenario-based Q&A blocks guide researchers through protocol optimization, data interpretation, and product selection, ensuring robust results and workflow confidence.

• Bradykinin as an Endothelium-Dependent Vasodilator: Applied

  2026-05-16

  Unlock the full experimental potential of Bradykinin as a potent endothelium-dependent vasodilator with detailed protocols and troubleshooting wisdom. Discover how APExBIO’s Bradykinin empowers vascular permeability and pain mechanism research with reproducibility and workflow clarity.

• GPR30 in Spinal CCK+ Neurons as a Modulator of Neuropathic P

  2026-05-15

  This study identifies the G protein-coupled estrogen receptor GPR30, expressed in spinal cholecystokinin-positive (CCK+) neurons, as a critical modulator of neuropathic pain. By demonstrating that GPR30 inhibition in these neurons reverses injury-induced pain hypersensitivity, the work highlights GPR30 as a promising target for mechanistic pain research and potential therapeutic intervention.

• Azathramycin A: Expanding Macrolide Strategies for Tuberculo

  2026-05-15

  Discover how Azathramycin A, a potent macrolide antibiotic, advances tuberculosis research by enabling nuanced exploration of protein synthesis inhibition and resistance pathways. This article uniquely connects biophysical assay design with translational applications, offering deeper assay guidance for scientists.

• L-NMMA Acetate in NOS Pathway Modulation: Applied Protocols

  2026-05-14

  L-NMMA acetate, a potent pan-NOS inhibitor, is transforming nitric oxide pathway research across regenerative medicine and inflammation models. This article delivers actionable workflows, troubleshooting strategies, and practical translation of recent findings for experimental success.

• Temafloxacin’s In Vitro Efficacy: Insights for Gram-Negative

  2026-05-14

  This article analyzes Hardy’s pivotal reference study evaluating temafloxacin’s in vitro activity against diverse Gram-negative pathogens, benchmarking it against earlier quinolones like cinoxacin. The findings highlight temafloxacin’s significantly improved potency and spectrum, with direct implications for antimicrobial research and resistance profiling.

• SU6656 Src Tyrosine Kinases Inhibitor: Protocols for Platele

  2026-05-13

  Leverage SU6656 Src tyrosine kinases inhibitor to boost hiPSC-derived platelet yield and sensitize tumor vasculature to radiotherapy. This guide decodes experimental workflows, protocol tweaks, and key troubleshooting strategies for maximizing both megakaryocyte polyploidization and antiangiogenic effects.

• CLK2 Inhibition to Overcome Platinum Resistance in Ovarian C

  2026-05-13

  This study uncovers the mechanistic role of Cdc2-like kinase 2 (CLK2) in mediating platinum resistance in ovarian cancer by enhancing DNA repair via BRCA1 phosphorylation. The findings suggest that targeting CLK2 may provide a new strategy for overcoming chemoresistance, with translational implications for splicing modulation research and therapeutic development.

15370 records 7/1025 page Previous Next First page 上5页 678910 下5页 Last page